YI: 111 Inc Analyst Median Target

Symbol and logo of brand 111, Inc. (YI)

111, Inc. is developing China's leading digital healthcare hub, integrating remote diagnostics with pharmaceutical sales to optimize distribution. The business relies on large-scale logistics and network effects, which, under strict Chinese regulatory oversight, limit the entry of new players. The current metric stands at 11.95, while this chart of the company's market valuation is supplemented by data on IT architect hiring and the stability of the technical core.

111, Inc (YI) - Analyst Consensus Forecast from 07/04/2022 to 11/11/2026

Metric breakdowns and analytics for 111, Inc. (YI)

- current quotes and average value forecast:
Market Price 111.com.cn|YI - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization 111 Inc|YI - Total Company Value
- company book value details:
Share Book Value 111, Inc.|YI - Book Capitalization|Market Value to Book Value 111.com.cn|YI - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital 111, Inc.|YI - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital 111.com.cn|YI - Company Debts|Debt to Book Value 111 Inc.|YI - Company Long-Term Debts|Company Short-Term Debts 111, Inc.|Quick Liquidity Indicator 111.com.cn
- earnings and valuation multiples indicators:
YI - Net Income|Expected Net Profit 111, Inc.|YI - P/E Multiple|Forward P/E Multiple 111.com.cn|YI - PEG Multiple|Enterprise Value to EBITDA Ratio 111 Inc|YI - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) 111, Inc.|YI - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months 111.com.cn|YI - Earnings per share growth this year|Earnings growth forecast for next year 111, Inc.
Fundamental company analysis:YI (111, Inc)
Signature product of 111 Inc.

To assess the fundamental value of YI, investors must compare the market price with the average target price calculations from leading investment banks. The analysts' consensus forecast aggregates professional business valuations, which is particularly critical for 111, Inc. given the stringent regulation of healthcare in the PRC and the presence of powerful network effects in pharmaceutical logistics.

Competing companies

CVS - Average Forecast Price|Analyst Consensus Forecast MCK (McKesson)|Analyst Median Target Cencora Inc (COR)|CAH - Price Target Chart|Forecast Levels Chart HSIC|PBH: Analyst Consensus Forecast|Wellgistics Health - Fair Value Consensus|RDGT (China Jo-Jo Drugstores) - Analyst Consensus Forecast|Analyst Consensus Forecast Universe Pharmaceuticals Inc.|Price Target Chart Biodexa Pharmaceuticals (BDRX)|HKPD (9zt.hk) - Fair Value Consensus|Price Target Chart BIMI Holdings Inc. BIMI|CJJD - Consensus Target|Walgreens - Analyst Consensus Forecast